198 related articles for article (PubMed ID: 11884288)
1. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice.
Aiello RJ; Bourassa PA; Lindsey S; Weng W; Freeman A; Showell HJ
Arterioscler Thromb Vasc Biol; 2002 Mar; 22(3):443-9. PubMed ID: 11884288
[TBL] [Abstract][Full Text] [Related]
2. Leukotriene B4 strongly increases monocyte chemoattractant protein-1 in human monocytes.
Huang L; Zhao A; Wong F; Ayala JM; Struthers M; Ujjainwalla F; Wright SD; Springer MS; Evans J; Cui J
Arterioscler Thromb Vasc Biol; 2004 Oct; 24(10):1783-8. PubMed ID: 15271789
[TBL] [Abstract][Full Text] [Related]
3. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms.
Subbarao K; Jala VR; Mathis S; Suttles J; Zacharias W; Ahamed J; Ali H; Tseng MT; Haribabu B
Arterioscler Thromb Vasc Biol; 2004 Feb; 24(2):369-75. PubMed ID: 14656734
[TBL] [Abstract][Full Text] [Related]
4. Endogenous monocyte chemoattractant protein-1 (MCP-1) protects mice in a model of acute septic peritonitis: cross-talk between MCP-1 and leukotriene B4.
Matsukawa A; Hogaboam CM; Lukacs NW; Lincoln PM; Strieter RM; Kunkel SL
J Immunol; 1999 Dec; 163(11):6148-54. PubMed ID: 10570305
[TBL] [Abstract][Full Text] [Related]
5. Blockade of the interaction of leukotriene b4 with its receptor prevents development of autoimmune uveitis.
Liao T; Ke Y; Shao WH; Haribabu B; Kaplan HJ; Sun D; Shao H
Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1543-9. PubMed ID: 16565390
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the pharmacological profile of the potent LTB4 antagonist CP-105,696 on murine LTB4 receptors in vitro.
Showell HJ; Breslow R; Conklyn MJ; Hingorani GP; Koch K
Br J Pharmacol; 1996 Mar; 117(6):1127-32. PubMed ID: 8882606
[TBL] [Abstract][Full Text] [Related]
7. The in vitro and in vivo pharmacologic activity of the potent and selective leukotriene B4 receptor antagonist CP-105696.
Showell HJ; Pettipher ER; Cheng JB; Breslow R; Conklyn MJ; Farrell CA; Hingorani GP; Salter ED; Hackman BC; Wimberly DJ
J Pharmacol Exp Ther; 1995 Apr; 273(1):176-84. PubMed ID: 7714764
[TBL] [Abstract][Full Text] [Related]
8. Antagonizing leukotriene B4 receptors delays cardiac allograft rejection in mice.
Weringer EJ; Perry BD; Sawyer PS; Gilman SC; Showell HJ
Transplantation; 1999 Mar; 67(6):808-15. PubMed ID: 10199727
[TBL] [Abstract][Full Text] [Related]
9. Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis.
Griffiths RJ; Pettipher ER; Koch K; Farrell CA; Breslow R; Conklyn MJ; Smith MA; Hackman BC; Wimberly DJ; Milici AJ
Proc Natl Acad Sci U S A; 1995 Jan; 92(2):517-21. PubMed ID: 7831322
[TBL] [Abstract][Full Text] [Related]
10. Systemic leukotriene B
Marvar PJ; Hendy EB; Cruise TD; Walas D; DeCicco D; Vadigepalli R; Schwaber JS; Waki H; Murphy D; Paton JF
J Physiol; 2016 Oct; 594(20):5975-5989. PubMed ID: 27230966
[TBL] [Abstract][Full Text] [Related]
11. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice.
Dawson TC; Kuziel WA; Osahar TA; Maeda N
Atherosclerosis; 1999 Mar; 143(1):205-11. PubMed ID: 10208497
[TBL] [Abstract][Full Text] [Related]
12. Leukocyte recruitment into developing atherosclerotic lesions: the complex interaction between multiple molecules keeps getting more complex.
Rosenfeld ME
Arterioscler Thromb Vasc Biol; 2002 Mar; 22(3):361-3. PubMed ID: 11884275
[No Abstract] [Full Text] [Related]
13. Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice.
Dol F; Martin G; Staels B; Mares AM; Cazaubon C; Nisato D; Bidouard JP; Janiak P; Schaeffer P; Herbert JM
J Cardiovasc Pharmacol; 2001 Sep; 38(3):395-405. PubMed ID: 11486244
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of leukotriene B4--triggered monocyte adhesion.
Friedrich EB; Tager AM; Liu E; Pettersson A; Owman C; Munn L; Luster AD; Gerszten RE
Arterioscler Thromb Vasc Biol; 2003 Oct; 23(10):1761-7. PubMed ID: 12947016
[TBL] [Abstract][Full Text] [Related]
15. The leukotriene B
Deng B; Lin Y; Ma S; Zheng Y; Yang X; Li B; Yu W; Xu Q; Liu T; Hao C; He R; Ding F
Kidney Int; 2017 Jul; 92(1):89-100. PubMed ID: 28318626
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of the leukotriene B4 receptor antagonist CP-105,696 in man following single oral administration.
Liston TE; Conklyn MJ; Houser J; Wilner KD; Johnson A; Apseloff G; Whitacre C; Showell HJ
Br J Clin Pharmacol; 1998 Feb; 45(2):115-21. PubMed ID: 9491823
[TBL] [Abstract][Full Text] [Related]
17. Commonly used leukotriene B4 receptor antagonists possess intrinsic activity as agonists in human endothelial cells: Effects on calcium transients, adhesive events and mediator release.
Johansson AS; Haeggström JZ; Palmblad J
Prostaglandins Leukot Essent Fatty Acids; 2011; 84(3-4):109-12. PubMed ID: 21183325
[TBL] [Abstract][Full Text] [Related]
18. 20-Hydroxy- and 20-carboxy-leukotriene (LT) B
Archambault AS; Poirier S; Lefebvre JS; Robichaud PP; Larose MC; Turcotte C; Martin C; Provost V; Boudreau LH; McDonald PP; Laviolette M; Surette ME; Flamand N
J Leukoc Biol; 2019 Jun; 105(6):1131-1142. PubMed ID: 30676680
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment.
Heller EA; Liu E; Tager AM; Sinha S; Roberts JD; Koehn SL; Libby P; Aikawa ER; Chen JQ; Huang P; Freeman MW; Moore KJ; Luster AD; Gerszten RE
Circulation; 2005 Jul; 112(4):578-86. PubMed ID: 16043658
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo effects of leukotriene B4 antagonism in a primate model of asthma.
Turner CR; Breslow R; Conklyn MJ; Andresen CJ; Patterson DK; Lopez-Anaya A; Owens B; Lee P; Watson JW; Showell HJ
J Clin Invest; 1996 Jan; 97(2):381-7. PubMed ID: 8567958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
